Prevention and treatment of cytomegalovirus infection and disease in heart transplant recipients

Current Opinion in Cardiology

Volumn 13, Issue 2, 1998, Pages 122-129

  Avery, Robin K ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; GLOBULIN; VIRUS ANTIGEN; VIRUS DNA;

ANTIGEN DETECTION; CLINICAL FEATURE; CYTOMEGALOVIRUS INFECTION; DISEASE ASSOCIATION; EARLY DIAGNOSIS; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; IMMUNE DEFICIENCY; MYCOSIS; OPPORTUNISTIC INFECTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; RISK; VASCULAR DISEASE;

EID: 0031958359     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001573-199803000-00009     Document Type: Review

References (110)

1. Rubin RH: Infection in the organ transplant recipient. In Clinical Approach to Infection in the Compromised Host, edn 3. Edited by Rubin RH, Young LS. New York: Plenum Medical Book Company; 1994:629-705. Definitive, authoritative overview of infections in solid-organ transplant recipients; the author defines many of the concepts in current use
2. Falagas ME, Snydman DR, Griffith J, Ruthazer R, Werner BG: Effect of cytomegalovirus infection status on first-year mortality rates among orthotopic liver transplant recipients: The Boston Center for Liver Transplantation CMVIG Study Group. Ann Intern Med 1997, 126:275-279.
3. Rubin RH: Impact of cytomegalovirus infection on organ transplant recipients. Rev Infect Dis 1990, 12(suppl 7):S754-S766.
4. Rubin RH: The indirect effects of cytomegalovirus infection on the outcome of organ transplantation. JAMA 1989, 261:3607-3609.
5. Singh N, Dummer JS, Kusne S, Breining MK, Armstrong JA, Makowka L, Starzl TE, Ho M: Infections with cytomegalovirus and other herpesviruses in 121 liver transplant recipients: transmission by donated organ and the effect of OKT3 antibodies. J Infect Dis 1988, 158:124-131.
6. George MJ, Snydman DR, Werner BG, Griffith J, Falagas ME, Dougherty NN, Rubin RH: The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Am J Med 1997, 103:106-113.
7. Hibberd PL, Tolkoff-Rubin NE, Cosimi AB, Schooley RT, Isaacson D, Doran M, Delvecchio A, Delmonico FL, Auchincloss H Jr, Rubin RH: Symptomatic cytomegalovirus disease in cytomegalovirus antibody seropositive renal transplant recipient treated with OKT3. Transplantation 1992, 53:68-72.
8. Swinnen LJ, Costanzo-Nordin MR, Fisher SJ, O'Sullivan EJ, Johnson MR, Heroux AL, Dizikes GJ, Pifarre R, Fisher RI: Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac transplant recipients. Engl J Med 1990, 323:1723-1728.
9. Hibberd PL, Tolkoff-Rubin NE, Conti D, Stuart F, Thistlethwaite JR, Neylan JF, Syndman DR, Freeman R, Lorber MI, Rubin RH: Preemptive ganciclovir therapy to prevent cytomegalovirus disease in antibody-positive renal transplant recipients. Ann Intern Med 1995, 123:39-26.
10. Snydman DR, Werner BG, Heinze-Lacey B, Berardi VP, Tilney NL, Kirkman RL, Milford EL, Cho SI, Bush HL Jr, Levey AS, et al: Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal transplant recipients. N Engl J Med 1997, 317:1049-1054.
11. Wagner TA, Ross H, Hunt S, Gamberg P, Valantine H, Merigan TC, Stinson EB: Prophylactic ganciclovir treatment reduces fungal as well as cytomegalovirus infections after heart transplantation. Transplantation 1995, 60:1473-1477.
12. Gorensek MJ, Stewart RW, Keys TF, McHenry MC, Babiak T, Goormastic M: Symptomatic cytomegalovirus infection as a significant risk factor for major infections after cardiac transplantation. J Infect Dis 1988, 158:884-887.
13. Smith PD, Saini SS, Raffeld M, Manischewitz JF, Wahl SM: Cytomegalovirus induction of tumor necrosis factor-alpha by human monocytes and mucosal macrophages. J Clin Invest 1992, 90:1642-1648.
14. Geist LJ, Monick MM, Stinski MF, Hunninghake GW: The immediate early genes of human cytomegalovirus upregulate tumor necrosis factor-alpha gene expression. J Clin Invest 1994, 93:474-478.
15. Docke WD, Prosch S, Fietze E, Kimel V, Zuckermann H, Klug C, Syrbe U, Kruger DH, von Baehr R, Volk HD: Cytomegalovirus reactivation and tumour necrosis factor. Lancet 1994, 343:268-269.
16. Pollard RB, Arvin AM, Gamberg P, Rand KH, Gallagher JG, Merigan TC: Specific cell-mediated immunity and infections with herpes viruses in cardiac transplant recipients. Am J Med 1982, 73:679-687.
17. Preiksaitis JK, Rosno S, Grumer C, Merigan TC: Infections due to herpesviruses in cardiac transplant recipients: role of the donor heart and immunosuppressive therapy. J Infect Dis 1993, 147:974-981.
18. Gorensek MJ, Stewart PW, Keys TF, McHenry MC, Goormastic M: A multivariate analysis of the risk of cytomegalovirus infection in heart transplant recipients. J Infect Dis 1988, 157:515-522.
19. Costonzo-Nordin MR, Swinnen LJ, Fisher SG, O'Sullivan EJ, Pifarre R, Heroux AL, Mullen GM, Johnson MR: Cytomegalovirus infections in heart transplant recipients: relationship to immunosuppression. J Heart Lung Transplant 1992, 11:837-846.
20. Kirklin JK, Naftel DC, Levine TB, Bourge RC, Pelletier GB, O'Donnell J, Miuller LW, Pritzker MR: Cytomegalovirus after heart transplantation: risk factors for infection and death: a multiinstitutional study. The Cardiac Transplant Research Database Group. J Heart Lung Transplant 1994, 13:394-404.
21. Krogsgaard K, Boesgaard S, Aldershvile J, Arendrup H, Mortensen SA, Petterson G: Cytomegalovirus infection rate among heart transplant patients in relation to anti-thymocyte immunoglobulin induction therapy: Copenhagen Heart Transplant Group. Scand J Infect Dis 1994, 26:239-247.
22. Hutter JA, Scott J, Wreghitt T, Higenbottam T, Wallwork J: The importance of cytomegalovirus in heart-lung transplant recipients. Chest 1989, 95:627-631.
23. Wreghitt TG, Hakim M, Gray JJ, Kucia S, Wallwork J, English TA: Cytomegalovirus infections in heart and heart and lung transplant recipients. J Clin Pathol 1988, 41:660-667.
24. Dummer JS, White LT, Ho M, Griffith BP, Hardesty RL, Bahnson HT: Morbidity of cytomegalovirus infection in recipients of heart or heart-lung transplants who received cyclosporine. J Infect Dis 1985, 152:1182-1191.
25. Powell KF, Bellamy AR, Catton MG, Cooper IP, Philip BA, Rainer SP, Coverdale HA, Croxson MC: Cytomegalovirus myocarditis in a heart transplant recipient: sensitive monitoring of viral DNA by the polymerase chain reaction. J Heart Transplant 1989, 8:465-470.
26. Arbustini E, Grasso M, Diegoli M, Percivalle E, Grossi P, Bramerio M, Campana C, Goggi C, Gavazzi A, Vigano M: Histopathologic and molecular profile of human cytomegalovirus infections in patients with heart transplants. Am J Clin Pathol 1992, 98:205-213.
27. Pucci A, Ghisetti V, Donegani E, Barbui A, David E, Fortunato M, Papandrea C, Pansini S, Zattera G, di Summa M, et al.: Histologic and molecular diagnosis of myocardial human cytomegalovirus infection after heart transplantation. J Heart Lung Transplant 1994, 13:1072-1080.
28. Ghisetti V, Barbui A, Rocci MP, Donegani E, Bobbio M, Pucci A, Papndrea C, Pansini S, Zattera G, Mollo F, et al.: Detection of human cytomegalovirus myocardial involvement by polymerase chain reaction during systemic infection and correlation with pp65 antigenemia and DNAemia in infected heart recipients. Transplantation 1996, 61:1072-1075.
29. Lowry RW, Adam E, Hu C, Kleiman NS, Cocanougher B, Windsor N, Bitar JN, Melnick JL, Young JB: What are the implications of cardiac infection with cytomegalovirus before heart transplantation? J Heart Lung Transplant 1994, 13:122-128.
30. Grattan MT, Moreno-Cabral CE, Starnes VA, Oyer PE, Stinson EB, Shumway NE: Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA 1989, 261:3561-3566.
31. Carlquist JF, Shelby J, Shao YL, Greenwood JH, Hammond ME, Anderson JL: Accelerated rejection of murine cardiac allografts by murine cytomegalovirus-infected recipients: lack of haplotype specificity. J Clin Invest 1993, 91:2602-2608.
32. Bunke M, Ganzel B, Gardner C: Increased late rejection in cytomegalovirus-immunoglobulin-M-positive heart transplantation patients. Transplant Proc 1995, 27(5 suppl 1):44-45.
33. Stovin PG, Wreghitt TG, English TA, Wallwork J: Lack of association between cytomegalovirus infection of heart and rejection-like inflammation. J Clin Pathol 1989, 42:81-83.
34. Fernando S, Booth J, Boriskin Y, Butcher P, Carrington D, Steel H, Tryhorn Y, Corbishley C, Keeling P, Murday A, et al.: Association of cytomegalovirus infection with post-transplantation cardiac rejection as studied using the polymerase chain reaction. J Med Virol 1994, 42:396-404.
35. Boriskin YS, Booth JC, Corbishley CM, Madden BP, McKenna WJ, Murday AJ, Steel HM: Human cytomegalovirus and acute rejection after heart transplantation are not directly associated. J Med Virol 1996, 50:59-70.
36. Koskinen P, Lemstrom K, Bruggeman C, Lautenschlager I, Hayry P: Acute cytomegalovirus infection Induces a subendothelial inflammation (endothelialitis) in the allograft vascular wall: a possible linkage with enhanced allograft arteriosclerosis. Am J Pathol 1994, 144:41-50.
37. Lemstrom K, Koskinen P, Bruning H, Bruggeman C, Aho P, Hayry P: Cytomegalovirus infection accelerates mRNA expression of several smooth muscle cell growth factors in the allograft vascular wall. Transplant Proc 1995, 27:566-567.
38. McDonald K, Rector TS, Braulin EA, Kubo SH, Olivari MT: Association of coronary artery disease in cardiac transplant recipients with cytomegalovirus injection. Am J Cardiol 1989, 64:359-362.
39. Grattan MT, Moreno-Cabral CE, Starnes VA, Oyer PE, Stinson EB, Shumway NE: Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA 1989, 261:3561-3566
40. Wu TC, Hruban RH, Ambinder RF, Pizzorno M, Cameron DE, Baumgartner WA, Reitz BA, Hayward GS, Hutchins GM: Demonstration of cytomegalovirus nucleic acids in the coronary arteries of transplanted hearts. Am J Pathol 1992, 140:739-747.
41. Mangiavacchi M, Frigerio M, Gronda E, Danzi GB, Bonacina E, Masciocco G, Olivia F, De Vita C, Pellegrini A: Acute rejection and cytomegalovirus infection: correlation with cardiac allograft vasculopathy. Transplant Proc 1995, 27:1960-1962.
42. Li F, Grauls G, Yin M, Bruggeman CA: Initial endothelial injury and cytomegalovirus infection accelerate the development of allograft arteriosclerosis. Transplant Proc 1995, 27:3552-3554.
43. Gulizia JM, Kandolf R, Kendall TJ, Thieszen SL, Wilson JE, Radio SJ, Costanzo MR, Winters GL, Miller LL, McManus BM: Infrequency of cytomegalovirus genome in coronary arteriopathy of human heart allografts. Am J Pathol 1995, 147:461-475.
44. Skowronski EW, Mendoza A, Smith SC Jr, Jaski BE: Detection of cytomegalovirus in paraffin-embedded postmortem coronary artery specimens of heart transplant recipients by the polymerase chain reaction: implications of cytomegalovirus association with graft atherosclerosis. J Heart Lung Transplant 1993, 12:717-723.
45. Van der Bij W, Schirm J, Torensma R, van Son WJ, Tegzess AM, The TH: Comparison between viremia and antigenemia for detection of cytomegalovirus in blood. J Clin Microbiol 1988, 26:2531-2535.
46. Koskinen P, Nieminen M, Mattila S, Lautenschlager I: Quantitative immunodetection of cytomegalovirus antigenemia in the clinical diagnosis of CMV infection after heart transplantation. Transplant Proc 1993, 25 (1 Pt 2):1426.
47. Iberer F, Halwachs-Baumann G, Rodl S, Pleisnitzer A, Wasler A, Auer T, Petutschnigg B, Muller H, Tscheliessnigg K, Wilders-Truschnig M: Monitoring of cytomegalovirus disease after heart transplantation: persistence of anti-cytomegalovirus IgM antibodies. J Heart Lung Transplant 1994, 13:405-411.
48. Mazzulli T, Rubin RH, Ferraro MJ, D'Aquila RT, Doveikis SA, Smith BR, The TH, Hirsch MS: Cytomegalovirus antigenemia: clinical correlations in transplant recipients and in persons with AIDS. J Clin Microbiol 1993, 31:2824-2827.
49. Iberer F, Tscheliessnigg K, Halwachs G, Auer T. Wasler A, Petutschnigg B, Schreier G, Muller H, Allmayer T, Prenner G, et al.: Cytomegalovirus after heart transplantation: definitions for the guidance of antiviral therapy. Scand J Infect Dis Suppl 1995, 99:100-103.
50. Grossi P, Minoli L, Percivalle E, Irish W, Vigano M, Gerna G: Clinical and virological monitoring of human cytomegalovirus infection in 294 heart transplant recipients. Transplantation 1995, 59:847-851.
51. Egan JJ, Barber L, Lomax J, Fox A, Yonan N, Rahman AN, Campbell CS, Deiraniya AK, Carroll KB, Craske J, et al.: Detection of human cytomegalovirus antigenaemia: a rapid diagnostic technique for predicting cytomegalovirus infection /pneumonitis in lung and heart transplant recipients. Thorax 1995, 50:9-13.
52. Freymuth F, Gennetay E, Petijean J, Eugene G, Hurault de Ligny B, Ryckelynck JP, Legoff C, Hazera P, Bazin C: Comparison of nested PCR for detection of DNA in plasma with pp65 leukocytic antigenemia procedure for diagnosis of human cytomegalovirus infection. J Clin Microbiol 1994, 32:1614-1618.
53. Konig L, Schumacher B, Pecher P, Keilich M, Gunther HU, Straeten G, Stegmann T: Evaluation of cytomegalovirus-polymerase chain reaction in graft dysfunction after heart transplantation. Transplant Proc 1995, 27:1963-1966.
54. Schowengerdt KO, Ni J, Denfield SW, Gajarksi RJ, Radovancevic B, Frazier HO, Demmler GJ, Kearney D, Bricker JT, Towbin JA: Diagnosis, surveillance, and epidemiologic evaluation of viral infections in pediatric cardiac transplant recipients with the use of the polymerase chain resection. J Heart Lung Transplant 1996, 15:111-1123.
55. Wolff C, Skourtopoulos M, Hornschemeyer D, Wolff D, Korner M, Huffert F, Korfer R, Kleesier K: Significance of human cytomegalovirus DNA detection in immunocompromised heart transplant patients. Transplantation 1996, 61:750-757.
56. Barber L, Egan JJ, Lomax J, Yonan N, Deiraniya AK, Turner AJ, Woodcock AA, Fox AJ: Comparative study of three PCR assays with antigenaemia and serology for the diagnosis of HCMV infection in thoracic transplant recipients. J Med Virol 1996, 49:137-144.
57. Toyoda M, Carlos JB, Galera OA, Galfayan K, Zhang X, Sun Z, Czer LS, Jordan SC: Correlation of cytomegalovirus DNA levels with response to antiviral therapy in cardiac and renal allograft recipients. Transplantation 1997, 63:957-963.
58. Randhawa PS, Manez R, Frye B, Ehrlich GD: Circulating immediate-early mRNA in patients with cytomegalovirus infections after solid organ transplantation. J Infect Dis 1994, 170:1264-1267.
59. Wolff D, Skourtopoulos M, Hornschemeyer D, Wolff C, Korner M, Korfer R, Kleesiek K: Longitudinal monitoring of latent and active human cytomegalovirus infections in peripheral blood of heart transplant recipients by single-tube nested RT-PCR. Microbiol Res 1996, 151:343-349.
60. Mazzulli T, Wood S, Chua R, Walmsley S: Evaluation of the Digene Hybrid Capture System for detection and quantitation of human cytomegalovirus viremia in human immunodeficiency virus-infected patients. J Clin Microbiol 1996, 34:2959-2962.
61. Kusne S, Manez R, Frye BL, St. George K, Abu-Elmagd K, Tabasco-Menguillon J, Fung JJ, Todo S, Rinaldo C, Ehrlich GD: Use of DNA amplification for diagnosis or cytomegalovirus enteritis after intestinal transplantation. Gastroenterology 1997, 112:1121-1128.
62. Buffone GJ, Frost A, Samo T, Demmler GJ, Cagle PT, Lawrence EC: The diagnosis of CMV pneumonitis in lung and heart/lung transplant patients by PCR compared with traditional laboratory criteria. Transplantation 1993, 56:342-347.
63. Badley AD, Patel R, Portela DF, Harmsen WS, Smith TF, Ilstrup DM, Steers JL, Wiesner RH, Paya CV: Prognostic significance and risk factors of untreated cytomegalovirus viremia in liver transplant recipients. J Infect Dis 1996, 173:446-449.
64. Abecassis MM, Koffron AJ, Kaplan B, Buckingham M, Muldoon JP, Cribbins AJ, Kaufman DB, Fryer JP, Stuart J, Stuart FP: The role of PCR in the diagnosis and management of CMV in solid organ recipients: what is the predictive value for the development of disease and should PCR be used to guide antiviral therapy? Transplantation 1997, 63:275-279.
65. Niubo J, Perez JL, Martinez-Lacasa JT, Garcia A, Roca J, Fabregat J, Gil-Vernet S, Martin R: Association of quantitative cytomegalovirus antigenemia with symptomatic infection in solid organ transplant patients. Diagn Microbiol Infect Dis 24:19-24.
66. Keay S, Bissett J, Merigan TC: Ganciclovir treatment of cytomegalovirus infections in iatrogenically immunocompromised patients. J Infect Dis 1987, 156:1016-1021.
67. Patel P, Snydman DR, Rubin RH, Ho M, Pescovitz M, Martin M, Paya CV: Cytomegalovirus prophylaxis in solid organ transplant recipients. Transplantation 1996, 61:1279-1289. Comprehensive summary and evaluation of the vast literature on CMV prophylaxis in organ transplant recipients.
68. Balfour HH, Chace BA, Stapleton JT, Simmons RL, Fryd DS: A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N Engl J Med 1989, 320:1381-1387.
69. Elkins CC, Frist WH, Dummer JS, Stewart JR, Merrill WH, Carden KA, Bender HW Jr.: Cytomegalovirus disease after heart transplantation: is acyclovir prophylaxis indicated? Ann Thorac Surg 1993, 56:1267-1272, discussion 1272-1273.
70. Dunn DL, Gillingham KJ, Kramer MA, Schmidt WJ, Erice A, Balfour HH Jr, Gores PF, Gruessner RW, Matas AJ, Payne WD, et al.: A prospective randomized study of acyclovir versus ganciclovir plus human immune globulin prophylaxis of cytomegalovirus infection after solid organ transplantation. Transplantation 1994, 57:876-884.
71. Laske A, Gallino A, Mohacsi P, Bauer EP, Carrel T, von Segesser LK, Turina MI: Prophylactic treatment with ganciclovir for cytomegalovirus infection in heart transplantation. Transplant Proc 1991, 23:1170-1173.
72. Merigan TC, Renlund DG, Keay S, Bristow MR, Starnes V, O'Connell JB, Resta S, Dunn D, Gamberg P, Ratkovec RM, et al.: A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. N Engl J Med 1992, 326:1182-1186.
73. Aguado JM, Gomez-Sanchez MA, Lumbreras C, Delgado J, Lizasoain M, Otero JR, Rufilanchas JJ, Noriega AR: Prospective randomized trial of efficacy of ganciclovir versus that of anti-cytomegalovirus (CMV) immunoglobulin to prevent CMV disease in CMV-seropositive heart transplant recipients treated with OKT3. Antimicrob Agents Chemother 1995, 39:1643-1645.
74. MacDonald PS, Keogh AM, Marshman D, Richens D, Harvison A, Kaan AM, Spratt PM: A double-blind placebo-controlled trial of low-dose ganciclovir to prevent cytomegalovirus disease after heart transplantation. J Heart Lung Transplant 1995, 14(1 Pt 1):32-38.
75. Gimenez D, Maria Arizon J, de la Torre J, Anguita M, Escauriaza J, Lopez Granados A, Mesa D, Torres F, Casares J, Concha M, Valles F: Valor de una pauta profilactica corta (7 dias) de ganciclovir en la prevencion de la enfermedad por citomegalovirus tras el trasplante cardiaco. Rev Esp Cardiol 1996, 49:35-40.
76. th Annual Meeting of the American Society of Transplant Physicians, 1996.
77. Gane E, Saliba F, Valdecasas GJC, O'Grady J, Pescovitz MD, Lyman S, Robinson CA: Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. Lancet 1997, 350:1729-1733. The first demonstration of the potential utility of oral ganciclovir in organ transplant recipients.
78. th Annual Meeting of the American Society of Transplant Physicians, 1997.
79. th Annual Meeting of the American Society of Transplant Physicians, 1997.
80. Schafers HJ, Wahlers T, Jurmann M, Fieguth HG, Milbradt H, Flik J, Haverich A: Hyperimmunoglobulin for cytomegalovirus prophylaxis following heart transplantation. J Hospital Infect 1988, 12(suppl D):61-63.
81. Havel MP, Laczkovics AM, Wolner E, Kurz RW, Popow-Kraupp T: Prophylactic use of hyperimmunoglobulin for cytomegalovirus infection in heart transplantation. Clin Ther 1989, 11:472-478.
82. Havel M, Teufelsbauer H, Laczkovics A, Kurz R, Wolner E: Cytomegalovirus hyperimmunoglobulin prophylaxis in the prevention of cytomegalovirus infection in immunosuppressed heart transplant patients. Transplant Proc 1990, 22:1805-1806.
83. Weimar W, Metselaar HJ, Balk AH, Mochtar B, Rothbarth PH, Jeekel J: Passive immunization to prevent cytomegalovirus disease after kidney and heart transplantation. Transplant Proc 1990, 22:229-232.
84. Metselaar HJ, Balk AH, Mochtar B, Rothbarth PH, Weimar W: Cytomegalovirus seronegative heart transplant recipients: prophylac-tic use of anti-CMV immunoglobulin. Chest 1990, 97:396-399.
85. Tinelli M, Percivalle E, Zambelli A, Grossi P, Maccabruni A: Cytomegalovirus prophylaxis by intravenous immunoglobulins in five heart transplanted patients. Boll Ist Sieroter Milan 1990, 69:459-467.
86. Freeman R, Gould FK, McMaster A: Management of cytomegalovirus antibody negative patients undergoing heart transplantation. J Clin Pathol 1990, 43:373-376.
87. Balk AH, Weimar W, Rothbarth PH, Meeter K, Metselaar HJ, Mochtar B, Simoons ML, et al.: Passive immunization against cytomegalovirus in allograft recipients: the Rotterdam Heart Transplant Program experience. Infection 1993, 21:195-200.
88. Boland GJ, Ververs C, Hene RJ, Jambroes G, Donckerwolcke RA, de Gast GC: Early detection of primary cytomegalovirus infection after heart and kidney transplantation and the influence of hyperimmune globulin prophylaxis. Transpl Int 1993, 6:34-38.
89. Valantine HA: Prevention and treatment of cytomegalovirus disease in thoracic organ transplant evidence for a beneficial effect of hyperimmune globulin. Transplant Proc 1995, 27(5 suppl 1):49-57.
90. Preiksaitis JK, Rosno S, Rasmussen L, Merigan TC: Cytomegalovirus infection in heart transplant recipients: preliminary results of a controlled trial of intravenous gamma globulin. J Clin Immunol 1982, 2(2 suppl):36S-41S.
91. Eisenmann D, Knipp H, Laube H, Stegmann T: Prevention of cytomegalovirus disease in heart recipients by prophylaxis with cytomegalovirus hyperimmune globulin plus oral acyclovir. Transplant Proc 1990, 22:2322-2323.
92. Valenza M, Czer LS, Pan SH, Aleksic I, Freimark D, Harasty DA, Admon D, Barath P, Blanche C, Trento A: Combined antiviral and immunoglobulin therapy as prophylaxis against cytomegalovirus infection after heart transplantation. J Heart Lung Transplant 1995, 14:659-665.
93. Martin M: Prophylactic cytomegalovirus management strategies. Transplant Proc 1995, 27(5 suppl 1):23-27.
94. Gajarski RJ, Rosenblatt HM, Denfield SW, Schowengerdt Ko, Price JK, Towbin JA: Outcomes among pediatric heart transplant recipients. Tex Heart Inst J 1997, 24:97-104.
95. Rubin RH: Preemptive therapy in immunocompromised hosts [editorial]. N Engl J Med 1991, 324:1057-1059.
96. Gerna G, Zipeto D, Parea M, Revello MG, Silini E, Percivalle E, Zavattoni M, Grossi P, Milanesi G: Monitoring of human cytomegalovirus infections and ganciclovir treatment in heart transplant recipients by determination of viremia, antigenemia, and DNAemia. J Infect Dis 1991, 164:488-498.
97. Iberer F, Tscheliessnigg KH, Halwachs G, Auer T, Wasler A, Petutschnigg B, Muller H, Freigassner M, Allmayr T, Hipmair G, et al.: CMV antigenemia (the lower matrix protein pp65), a marker for the guidance of antiviral therapy in cytomegalovirus disease after orthotopic heart transplantation. Wien Klin Wochenschr 1995, 107:718-722.
98. th Annual Meeting of the American Society of Transplant Physicians 1997.
99. th Annual Meeting of the American Society of Transplant Physicians, 1997.
100. Falagas ME, Snydman DR: Recurrent cytomegalovirus disease in solid-organ transplant recipients. Transplant Proc 1995, 27(5 suppl 1):34-37.
101. Boivin G, Erice A, Crane D, Dunn DL, Balfour HH Jr: Ganciclovir susceptibilities of cytomegalovirus isolates from solid organ transplant recipients with CMV viraemia after antiviral prophylaxis. J Infect Dis 1991, 163:716-719.
102. Winston DJ, Wirin D, Shaked A, Busuttil RW: Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients. Lancet 1995, 346:69-74.
103. Lurain NS, Ammons HC, Kapell KS, Yeldandi VV, Garrity ER, O'Keefe JP: Molecular analysis of human cytomegalovirus strains from two lung transplant recipients with the same donor. Transplantation 1996, 62:497-502.
104. Reusser P, Cordonnier C, Einsele H, Engelhard D, Link D, Locasciulli A, Ljungman P: European survey of herpesvirus resistance to antiviral drugs in bone marrow transplant recipients. Bone Marrow Transplant 1996, 17:813-817.
105. Rosen HR, Benner KG, Flora KD, Rabkin JM, Orloff S, Olyaei A, Chou S: Development of ganciclovir resistance during treatment of primary cytomegalovirus infection after liver transplantation. Transplantation 1997, 63:476-478.
106. George MJ, Snydman DR, Werner BG, Dougherty NN, Griffith J, Rohrer RH, Freeman R, Jenkins R, Lewis WD: Use of ganciclovir plus cytomegalovirus immune globulin to treat CMV pneumonia in orthotopic liver transplant recipients. Transplant Proc 1993, 25(5 suppl 4):22-24.
107. Reed EC, Bowden RA, Dandliker PS, Lilleby KE, Meyers JD: Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants. Ann Intern Med 1988, 109:783-788.
108. Schmidt GM, Horak DA, Niland JC, Duncan SR, Forman SJ, Zaia JA: A randomized, controlled trail of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants. N Engl J Med 1991, 324:1005-1011.
109. Lalezari JP, Stagg RJ, Kuppermann BD, Holland GN, Kramer F, Ives DV, Youle M, Robinson MR, Drew WL, Jaffe HS: Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS: a randomized, controlled trial. Ann Intern Med 1997, 126:257-263.
110. Feinberg J, Cooper D, Hurwitz S: Phase III international study of valaciclovir (VACV) for cytomegalovirus (CMV) prophylaxis in patients with advanced HIV disease [abstract Th. B. 300]. Int Cont AIDS 1996, 11:225.